ESR1 and breast carcinoma: The immunophenotypic features of breast carcinomas arising in BRCA1 mutation carriers have also been evaluated by Palacios et al, showing that only 25% of BRCA1-associated tumors were ER positive and PR negative, whereas all cases were HER2 negative [24].